HealthFlex
×
  • About Us
    • Company Management
    • Meet Our Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
    • Careers
  • Technologies
    • Oncoprex® Delivery System
    • Reqorsa® Gene Therapy
    • GPX-002
  • Programs
    • Oncology
    • Diabetes
  • Clinical Trials
    • Pipeline
    • ONC-001
    • ONC-002
    • Acclaim-1
    • Acclaim-3
    • DIA-001 and DIA-002
    • Expanded Access Policy
  • Investors
    • Company Profile
    • Stock Information
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder FAQ
    • Downloads
    • Events
  • News
    • Press Releases
    • Blog Posts
    • Media Coverage
    • Videos
  • Contact
Gina Johnson

Gina Johnson

Senior Manager, Stability & Lifecycle Management

Gina Johnson serves as Genprex’s Senior Manager, QC, Stability & Product Lifecycle Management. Ms. Johnson’s role focuses on establishing a robust stability program for all the excipients and drug products at Genprex in addition to implementation of software and definition of CQAs and testing strategies for the next phases of clinical trials. She is responsible for managing and reviewing final drug release and stability data to support release and stability protocols of raw materials and final drug products. She ensures that all procedures and processes meet internal quality standard as well as external regulations specific to pre-clinical, clinical and commercial manufacturing.

Ms. Johnson has more than five years of combined experience working in Quality Control in the pharmaceutical and biotechnology industries and in the cell and gene therapy field.

Prior to joining Genprex, Gina was a Senior QC Analyst at Immatics, where she established the microbiology department and was responsible for developing microbiological assays and managing testing by compendial method. Prior to that, she worked at Lonza in the QC department where she was responsible for release testing, stability assays, assay qualifications and validation studies.

Ms. Johnson holds a masters degree in molecular biotechnology from the University of Houston and a BS in biology from Houston Baptist University.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

(877) 774-GNPX (4679)

3300 Bee Cave Road, Suite 650-227 Austin, TX 78746

Quick Links

  • About Us
  • Clinical Trials
  • Investors
  • Downloads
  • Press Releases
  • X
  • Facebook
  • LinkedIn

Latest News

  • Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer Apr 30
  • Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting Apr 28
  • Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting Apr 22
  • Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy Apr 21
Designed and Secured by Barsec
Copyright ©2026 all rights reserved.
Home - Privacy Policy - Terms of Use